3 days ago
Hengrui Shares Jump on GSK Deal Worth Up To $12 Billion
Jiangsu Hengrui Pharmaceuticals Co. shares rallied to their highest levels in four years after GSK Plc agreed to pay $500 million upfront for the company's potential chronic lung disease treatment.
The firm's Shanghai-listed stock rose as much as 8.16% to reach its highest level since July 2021, while its Hong Kong-listed shares were up as much as 10.95% on Monday.
